However, many programs struggle to deliver on that design. More than 1 in 3 physicians report that prior authorization (PA) criteria are rarely or never evidence-based and only 16% of physicians who take part in peer-to-peer reviews say the health plan clinician was appropriately qualified. The concept isn’t broken, but for many programs the execution isn’t matching the intent.

What Peer-to-Peer Review Is For

When the initial UM review applies criteria to available documentation, the peer-to-peer conversation adds clinical context that documentation alone can’t capture, such as why a member needs this dosage, reasons an alternative won’t work, or what’s already been tried.

Done well, peer-to-peer review is a clinical safety net. When two physicians can discuss the nuances of a member’s case and clinical evidence, inappropriate adverse determinations go down, and treating physicians have confidence that the process was substantive, not just procedural.

Done poorly, peer-to-peer is a scheduling hurdle that ends in a five-minute call with a generalist reviewer who can’t meaningfully evaluate the case. This version doesn’t reduce inappropriate determinations. It generates them.

Building a Peer-to-Peer Program That Works

The fix starts with two things: who’s doing the review and how quickly it happens.

Specialty-matched review means the physician on the plan’s side has current, relevant clinical expertise in the condition and treatment under review. When a pediatric neurologist calls about a complex seizure management case, the reviewer should be a pediatric neurologist, not a family medicine physician. That match is what makes the conversation genuinely peer-to-peer, and it’s what produces accurate determinations. 

This is no longer just a best practice. A growing number of states, including Alaska, Nebraska, Illinois, New York, and Texas, now require same-specialty or same-or-similar-specialty reviewers for medical necessity determinations, and a bipartisan federal bill reintroduced in 2025 would extend that standard to Medicare, Medicare Advantage, and Part D plans. Specialty mismatch is turning from a quality gap into regulatory exposure. 

It also fills a gap that’s easy to underestimate: the blind spots that inevitably creep into any physician’s knowledge base. Based on the pace of medical innovation, it’s nearly impossible for every clinician to stay current across every treatment protocol. A specialty-matched reviewer brings that current evidence into the conversation, keeping the treating physician informed on developments in treatment procedures and clinical guidelines relevant to the case. 

When blind spots go unchecked, the consequences are specific: inaccurate diagnoses, ineffective treatments, exposure to unnecessary treatments, and unnecessary out-of-pocket costs for members and their families. A specialty-matched reviewer protects members from unnecessary or potentially harmful care by giving the treating physician the current evidence and clinical context needed to get the approach right. When the determination is right the first time, the member, provider, and plan all benefit.

For example, in a recent blog our team highlighted how pediatric psychiatric cases are uniquely complex. A 15-year-old with severe depression may also carry a trauma history, a learning disability, and a home environment that is destabilizing. Comorbidity is the norm in this population and untangling it requires a specialist reviewer who understands how these conditions interact developmentally. If this case required a peer-to-peer review, a pediatric subspecialist would be appropriate. 

Turnaround time matters because a peer-to-peer review that takes three days to schedule is one that may not happen. The treating physician’s focus shifts to other urgent cases, the member waits, and the determination gets made without the conversation to inform it.

For health plans evaluating their peer-to-peer program — whether building internally or working with a review partner — a few criteria separate programs that work from programs that don’t.

1. The process of specialty matching: A large reviewer panel is only useful if the matching methodology connects the right case to the right reviewer consistently.
2. TAT reporting against real SLAs, not averages: Average turnaround can mask significant variation. Ask for distribution data on what percentage of cases meet the contracted timeline, and what happens to the ones that don’t.
3. Confirmed accreditation: URAC dual accreditation (Health Utilization Management and Independent Review Organization) and NCQA certification are baseline indicators that the program meets national standards for clinical review quality.
4. The escalation pathway: When a peer-to-peer conversation doesn’t resolve the case, what happens next? A defined, transparent process for escalation protects both the member and the plan. A growing number of states now require plans to publish their prior authorization requirements and timelines online, so ask whether a partner’s escalation path is documented and available to providers before a case ever reaches peer-to-peer.
5. How technology is used: The right technology can accelerate scheduling, documentation, and case routing, but it never replaces clinical judgment. 

The Conversation That Pays for Itself

Health plans that get peer-to-peer right do more than treat it as a regulatory checkbox. They treat peer-to-peer reviews as the highest-value conversation in their UM process — the one that protects members, earns physician trust, and gets the clinical decision right before it becomes an appeal. The plans that invest in specialty-matched review and hold their programs to real turnaround and quality standards ultimately see the difference on both sides of the ledger.

The post Getting Peer-to-Peer Reviews Right appeared first on MRIoA.

Medical Review Institute of America (MRIoA) is proud to announce its designation as the inaugural Community Impact Partner of the Texas Association of Community Health Plans (TACHP).
This partnership reflects a shared commitment to advancing community-based healthcare in Texas by fostering stronger connections between community health plans and mission-aligned organizations dedicated to improving health outcomes for Texas Medicaid members and the communities they serve.

As TACHP’s first Community Impact Partner, MRIoA looks forward to collaborating with health plan leaders across the state to support innovation, encourage knowledge-sharing, and help address some of healthcare’s most pressing challenges through education, collaboration, and shared problem-solving.

“We are honored to serve as TACHP’s inaugural Community Impact Partner,” said Chris Brandl, Senior Director of Growth at MRIoA “Community health plans play a critical role in delivering accessible, high-quality care to Texans. We are excited to support TACHP’s efforts to bring together organizations that share a commitment to improving health outcomes and strengthening the communities they serve.”

Through the Community Impact Partnership, MRIoA will support TACHP’s mission to:

• Strengthen partnerships between community health plans and mission-aligned organizations offering innovative solutions that support Texas Medicaid members and communities.
• Create opportunities for collaboration, education, and shared problem-solving on key healthcare challenges.

“We’re proud to welcome MRIoA as TACHP’s inaugural Community Impact Partner,” said Janet Walker, President and CEO of the Texas Association of Community Health Plans. “This partnership represents the kind of collaboration that helps drive new ideas, shared learning, and meaningful progress for the more than 1.7 million Texans served by our member health plans. We look forward to working together to support healthier communities across Texas.”

Together, MRIoA and TACHP look forward to building meaningful relationships, fostering productive dialogue, and supporting initiatives that help improve the health and well-being of communities throughout Texas.

About TACHP
The Texas Association of Community Health Plans (TACHP) represents community-based health plans that provide access to quality healthcare for communities across Texas. Through advocacy, collaboration, and innovation, TACHP supports its members in advancing healthcare quality, access, operational readiness, and long-term community impact. For more information, visit www.tachp.org

About MRIoA
Founded in 1983, Medical Review Institute of America, LLC (MRIoA) is a leading clinical review company in the United States. With one of the largest and most extensive clinical review networks, industry-leading turnaround times, and utilization review licensing in all states that require it, MRIoA’s professionalism, enthusiasm, and collaborative approach are transforming clinical care delivery nationwide. MRIoA is a technology-enabled provider of clinical insights to payers and patients through analytics and evidence-based clinical opinions derived from independent specialty reviews and virtual second opinion solutions that empower better decision-making.

The post MRIoA Named Inaugural Community Impact Partner of TACHP, Advancing Collaboration for Texas Communities appeared first on MRIoA.

There are several cost drivers that need attention. One lever for cost management is utilization management, which can responsibly remove unnecessary cost: care in an inappropriate setting, treatment the evidence does not support, and determinations that do not hold up and return as appeals. Two shifts make that possible.

1. The reviewer is qualified for the case. The recent AMA survey found that only 16 percent of physicians say the health plan representative in a peer-to-peer review is often or always appropriately qualified. A determination made by a clinician matched to the specialty and the clinical question is more accurate, more defensible, and less likely to be overturned, which is precisely the outcome now visible in public metrics. Work with a UM partner whose model is built with a broad network of actively practicing, same-specialty physician reviewers licensed in all 50 states, so the person reviewing the case actually practices in the field.
2. Focus on where care is delivered, not just whether it is approved. Recent reporting on hospital market consolidation found the same procedure priced at more than double from one facility to another in the same region, driven by market power rather than any clinical difference. Approving a medically necessary service is only half the decision; the setting can change its cost by a wide margin. Review that surfaces appropriate, lower-cost sites of care captures spend that a simple approve-or-redirect decision never reaches.

What better UM looks like in practice

For plans trying to manage medical trend without adding review burden, four moves matter most.

• Concentrate review where cost and variability are highest. Pull low-value, low-yield requests off the prior authorization list and focus clinical attention on high-cost, high-variability services. This aligns with the federal reductions rather than fighting them.
• Modernize the workflow, keep the physician in the decision. Tech-enabled intake and routing shorten turnaround and help meet CMS-0057-F timeframes of 72 hours for expedited and seven calendar days for standard requests, while physician reviewers make every determination. Technology enables the process; clinicians make the call.
• Treat determination quality as the number that matters. Same-specialty, physician-led review produces more accurate, more defensible decisions, reducing the appeals and rework that erase any short-term savings, and standing up to public reporting.
• Use your own review data. Benchmarking and analytics across review activity surface the root causes of unnecessary prior authorization and spend, turning individual determinations into operational improvement.

Utilization management is no longer a private cost lever a plan can turn up quietly. It is a published, comparable measure of clinical judgment. The plans that lower cost from here will be the ones whose reviews are appropriate, defensible, and delivered by the right clinician, because that is now the same thing as the cost strategy that survives public scrutiny. That is the standard MRIoA was built to meet: clarity and confidence in every clinical decision.

The principles behind better utilization management extend across every part of a health plan’s book of business. Specialty pharmacy is one of the highest-stakes areas: as drug costs continue to climb, the quality of the clinical review behind each determination matters as much as the decision itself. Safeguarding Care by Rethinking Utilization Management for High-Cost Specialty Drugs examines what rigorous, independent specialty drug UM actually looks like in practice. And because the regulatory environment shapes what plans are required to do, not just what they choose to do, Compliance Is a Business Risk You Can’t Ignore outlines how state and federal PA reform is raising the stakes for every clinical operations team.

To see how physician-led review ensures members receive appropriate care, schedule a consultation with our clinical team at mrioa.com.

The post The Importance of Utilization Management Just Increased appeared first on MRIoA.

Join MRIoA’s Fall 2026 Regulatory Roundtable for a practical look at what’s coming and how to assess whether your organization is ready. The session is built for compliance, clinical, operational, and utilization management leaders who need to turn regulatory change into operational decisions.

Wednesday, Oct. 7 | 1 p.m. EDT
Register here →

What You’ll Gain:

• A clear view of the 2027 implementation landscape and the common themes running through this year’s state legislation
• How new requirements may affect review standards, AI-supported review, prior authorization reporting and publication obligations, and electronic prior authorization readiness
• Practical considerations for assessing policy, process, delegation, technology, and documentation readiness

States on the Radar:

Alaska, Colorado, Delaware, Georgia, Illinois, Iowa, Kentucky, Louisiana, Minnesota, New Hampshire, New Mexico, New York, Oregon, Virginia, and Washington, with California still under watch.

Why It Matters:

State requirements rarely arrive all at once, and they rarely line up neatly. Plans operating across multiple states will need to reconcile different definitions, timelines, and reporting obligations inside the same workflows. Organizations that start assessing readiness in 2026 have room to adjust policies, retrain teams, and validate documentation before the requirements take effect. Organizations that wait will be doing the same work against a deadline.

Led by Aja Leichliter, Vice President and Chief Compliance Officer at MRIoA, this session draws on more than 20 years of experience across state utilization review and independent review organization mandates, URAC and NCQA standards, and federal prior authorization rules.

Register for the Fall 2026 Regulatory Roundtable →

The post Fall 2026 Regulatory Roundtable appeared first on MRIoA.

UM Touches Nearly Every Care Decision, Yet It’s Widely Misunderstood

Utilization management shapes nearly every significant care decision made in U.S. healthcare, yet it remains one of the least understood functions in the system, often reduced in shorthand to “the prior auth department.” That framing was already too narrow when the Institute of Medicine (IOM) first studied the field in 1989, and it’s even less accurate now.

Two forces make this the moment to understand UM more precisely. New CMS operational requirements take effect January 1, 2026, under the CMS Interoperability and Prior Authorization Final Rule (CMS-0057-F). And physician sentiment has become impossible to ignore: in the 2025 AMA Prior Authorization Physician Survey, 95% of physicians say prior authorization processes delay access to necessary care.

UM began as a cost-containment tool. The programs that hold up under regulatory and clinical scrutiny today are the ones that have evolved into a clinical quality discipline instead.

What Is Utilization Management?

The field’s standard definition comes from the Institute of Medicine’s 1989 report: techniques used by, or on behalf of, purchasers of health benefits to manage costs by influencing care decisions through case-by-case assessment of appropriateness.

In practice, that plays out across three review windows: prospective review (prior authorization), concurrent review, and retrospective review, backed by peer review, appeals, and independent or external review as the system’s checks on any single determination. Prior authorization is one component of UM, working as a clinical quality tool applied before care is delivered, not a standalone product or a cost-cutting mechanism on its own.

Where Did Utilization Management Come From?

UM’s roots trace to the mid-1960s and 1970s, when Medicare and Medicaid created formal utilization review processes, and Congress established Professional Standards Review Organizations in 1972 to evaluate medical necessity with peer-review boards of care delivered through federal healthcare programs. Through the 1980s, employers and insurers adopted utilization review widely as health costs climbed, and UM grew into a private-sector industry.

The IOM’s 1989 report gave the field a definition, legitimacy, and its first serious quality critique. The managed care backlash of the 1990s followed, and accreditation bodies including URAC and the National Committee for Quality Assurance (NCQA), emerged to standardize review quality and independence. Evidence-based clinical criteria matured through the 2000s and 2010s as external review rights expanded under state law and the Affordable Care Act. The 2020s have brought a wave of regulatory modernization: electronic prior authorization, mandated turnaround times, transparency reporting, and state-level reform, culminating in CMS-0057-F.

What Makes a Utilization Management Program High-Quality?

Not all UM programs are built the same, and the gap between a strong program and a weak one shows up in five places.

Evidence-based criteria, applied consistently. Determinations should be grounded in current clinical literature, not blanket rules applied without regard to the individual case. URAC’s accreditation standards build consistency and evidence-based practice into the review process itself.

The right reviewer for the case. Quality review means same-specialty physician review, and, where required, review by a physician licensed in the same state as the patient, per URAC’s standards.

Speed as a quality metric, not just an operational one. Turnaround time is now a compliance requirement. The guidelines under CMS-0057-F set a 72-hour standard for expedited requests and 7 calendar days for standard requests.

Independence and conflict-of-interest safeguards. No incentive should be tied to determination outcomes. That independence is the premise behind the independent review organization model and behind URAC’s dual accreditation structure.

Transparency in the decision and the path to challenge it. Every determination needs a specific, transparent reason and a meaningful appeals path, with peer-to-peer dialogue available in place of one-way adjudication. CMS-0057-F formalizes several of these requirements for impacted payers.

What’s Changing in Utilization Management?

The operational provisions of CMS-0057-F took effect January 1, 2026: standardized decision timeframes, specific reasons required for adverse determinations, and public prior authorization metrics, with impacted payers’ first reports due March 31, 2026. Fast Healthcare Interoperability Resources (FHIR) API requirements and more are required by January 1, 2027.

States haven’t waited for federal action. A wave of states enacted prior authorization reform in 2024 and 2025, with more than a dozen in 2024 alone, and requirements now vary meaningfully by state on gold-carding, decision timelines, and transparency. Health plan leadership evaluating a UM partner should confirm the current state count against the AMA’s tracker before assuming uniform requirements across their footprint.

The industry has also made its own commitments. In June 2025, over 60 health insurers pledged to reforms including ensuring clinical denials get reviewed by a qualified clinician and expanding real-time responses. Physicians remain skeptical it will hold: the same 2025 AMA survey found only one in three physicians believe the pledge will make a meaningful difference, and just one in four believe medical-necessity denials are consistently reviewed by an appropriately qualified clinician today. Both data points are worth holding in mind at once: the commitments are real, and so is the skepticism about whether they’ll be honored in practice.

Technology’s role in UM is also shifting, though not in the direction some assume. The programs earning trust are using intake automation, criteria surfacing, and analytics to reduce unnecessary prior authorization volume, not to make determinations. Every one of those tech-enabled workflows still routes the actual decision to a physician reviewer.

For a health plan or TPA evaluating a UM partner in 2026, confirm these five criteria—regardless of state or line of business:

• Evidence-based criteria, applied consistently
• Specialty-matched physician review
• Accreditation through URAC or NCQA
• Measured and reported turnaround time
• Peer-to-peer dialogue available
• Analytics designed to reduce review volume, not increase throughput

How MRIoA Approaches Clinical Review

Medical Review Institute of America (MRIoA) has operated as a clinically driven utilization management partner since 1983. That 40-plus year track record is backed by URAC dual accreditation across Health Utilization Management and Independent Review Organization, plus NCQA accreditation, a network of 700-plus state-matched specialists across 150-plus specialties, and licensure in all 50 states.

Every case is matched to a same-specialty physician reviewer, with MRIoA’s technology streamlining intake and workflow so that reviewers can focus on the clinical judgment only they can provide. On MRIoA’s own reviews, that structure supports 98%+ turnaround-time performance, 99%+ quality performance, and more than 2.4 million reviews completed per year.

UM’s 40-year history is really the industry learning, sometimes the hard way, that cost and quality aren’t competing goals when reviews are clinically led. Health plans and at-risk providers evaluating a UM partner can talk with MRIoA’s clinical review team about benchmarking their UM program against the standard outlined above.

Talk with MRIoA’s clinical review team about your UM program. Click here to learn more.

Frequently Asked Questions

What is utilization management in healthcare?

Utilization management is the set of clinical review processes payers use to confirm that requested care is medically necessary and appropriate. It includes prospective review (prior authorization), concurrent review, and retrospective review, anchored to the IOM’s 1989 definition of the field.

What are the three types of utilization review?

Prospective review happens before care is delivered and includes prior authorization. Concurrent review happens during an ongoing course of care, such as an inpatient stay. Retrospective review happens after care has been delivered, evaluating appropriateness after the fact.

Is prior authorization the same as utilization management?

No. Prior authorization is one prospective component of UM, not the whole discipline. UM also includes concurrent and retrospective review, plus peer review, appeals, and independent or external review.

What does “medical necessity” mean in a clinical review?

A determination that a requested service is appropriate for the patient’s condition based on current clinical evidence, assessed case by case rather than through a blanket rule. Quality reviews apply this standard through same-specialty physician judgment, not automated criteria alone.

What makes a utilization management program high-quality?

Evidence-based criteria applied consistently, specialty-matched physician review, independence from outcome-based incentives, measured turnaround time, and transparency in both the determination and the appeals path.

What are the CMS prior authorization requirements for 2026?

Under CMS-0057-F, impacted payers must decide expedited requests within 72 hours and standard requests within 7 calendar days, provide specific reasons for adverse determinations, and publicly report prior authorization metrics, with first reports due March 31, 2026.

The post The Evolution of Utilization Management: From Cost Containment to Clinical Quality appeared first on MRIoA.

Public reporting requirements reveal what happens without that discipline. A January 2026 KFF analysis found that Medicare Advantage insurers made nearly 53 million prior authorization determinations in 2024, and 80.7% of appealed denials were partially or fully overturned, a pattern consistent since 2019. A June 2026 HHS OIG report found 95% of appealed skilled nursing facility denials overturned, language OIG itself used to say this “raises concerns” about the initial determinations.

Review quality is the variable that determines whether UM functions as a clinical quality tool or a source of rework, provider abrasion, and regulatory exposure.

What Quality Actually Means in a Clinical Review

“Quality” gets used loosely in UM. Measured precisely, it comes down to four dimensions: the right reviewer, current evidence, first-pass accuracy, and defensible documentation.

The reviewer-match gap is where the industry’s own data is most uncomfortable. In the 2025 AMA Prior Authorization Physician Survey, only 24% of physicians say medical-necessity denials are consistently reviewed by a licensed, qualified clinician, and just 16% say the health plan representative in a peer-to-peer review often or always has the appropriate credentials. The full survey data breaks this down further by specialty and line of business.

First-pass accuracy is what overturn rates, reviewer consistency, and audit scores are actually measuring, and it’s built into accreditation for a reason: URAC’s utilization review standards set the timeframe and process expectations that a defensible review has to meet. Worth noting for a full picture, not just a favorable one: KFF’s own analysis points out that high overturn rates can also reflect incomplete documentation at the initial request, not only reviewer error. That’s a reason complete information capture belongs inside the definition of quality, not outside it.

What Members Gain When the Review Is Right the First Time

An overturned appeal represents care a provider already ordered and a plan later agreed was necessary, just delayed by the extra step of appealing it, as KFF frames it. That delay isn’t neutral. In the 2025 AMA survey, more than 1 in 4 physicians reported that prior authorization led to a serious adverse event for a patient in their care.

Quality protects members in both directions at once: confirming that requested care is evidence-based and appropriate, which is what prior authorization is designed to do as a clinical quality tool, and confirming that appropriate care isn’t needlessly delayed by a review that gets it wrong the first time. Getting both of those directions right, consistently, is what a health plan owes the members whose care depends on the decision.

What Providers Gain: A Peer Worth Talking To

Provider abrasion around prior authorization usually gets treated as a network relations problem. It’s more accurately a quality symptom. Physicians report completing 40 prior authorizations per week on average, and 94% say PA contributes to burnout, according to the AMA. Underneath the volume, the skepticism is specifically about who’s on the other end of the review.

Specialty matching is the structural fix. When peer-to-peer review means a same-specialty physician talking to another physician, the conversation functions as clinical dialogue instead of an obstacle to route around, and a determination that redirects care to a more appropriate option keeps its credibility with the ordering provider. Fewer resubmissions and escalations follow from that one upstream decision: who reviews the case in the first place.

The Economics: You Pay for Review Quality Either Way

A low-quality determination gets paid for three times:

• Once in the original review
• Again in the appeal it triggers
• Third time in downstream exposure

For CMS-0057-F payers, public reporting makes the first two visible to regulators, providers, and members directly; plans outside that scope don’t face public disclosure, but the underlying costs still show up in appeal volume and provider relationships. The third is easy to overlook in a procurement decision built around unit price: KFF’s analysis of post-acute care denials notes that independent review entity reversals can negatively affect a plan’s star ratings.

A quality evaluation looks at what predicts first-pass accuracy before a single case is reviewed:

• URAC or NCQA accreditation
• Depth of a specialty-matched physician panel, all-state licensure
• Documented, audited quality program the partner is willing to show you

How MRIoA Builds Quality Into Every Review

MRIoA has operated as a clinically driven utilization management partner for more than 40 years, built specifically around the reviewer-match and first-pass-accuracy dimensions of quality described in this article. That track record is backed by URAC dual accreditation across Health Utilization Management and Independent Review Organization, NCQA accreditation, HITRUST certification, a network of 700-plus state-matched physician specialists across 150-plus specialties, and licensure in all 50 states.

MRIoA’s tech-enabled workflows streamline intake and case routing, with every determination made by a physician reviewer matched to the case. That structure supports 99%+ quality and 98%+ turnaround-time performance across more than 2.4 million reviews per year, the kind of first-pass accuracy that keeps a plan off the overturn-rate scoreboard rather than on it.

A Midwest Blue Cross Blue Shield plan partnered with MRIoA to eliminate a sizeable medical director review backlog while sustaining more than 98% quality and turnaround-time performance throughout. Health plans, TPAs, and PBMs evaluating a UM partner’s quality program are welcome to schedule a consultation with MRIoA’s clinical review team to benchmark their program’s quality metrics against that standard.

The post Quality in Clinical Review: The UM Metric That Pays for Itself appeared first on MRIoA.

A 14-year-old with high-functioning autism spectrum disorder (ASD) is denied 15 hours.

Both determinations could be wrong.

Medical directors understand this juxtaposition: autism-related utilization management (UM) is a lose-lose if you get it wrong in either direction. Deny too aggressively and you’re exposed to parity complaints, member grievances, and litigation. Approve everything without clinical scrutiny and you’re failing members who need the right services, not just more services. At the end of the day, neither outcome serves the member.

A practical path between these two failure modes exists, but it requires clinical precision at the review level, not policy reflexes applied at scale.

Why Autism UM Is Uniquely Hard to Calibrate

The challenge starts with the condition itself. The 4-year-old and the 14-year-old in our example above require different clinical reasoning, different intensity benchmarks, and different outcome measures — but both can land in the same review queue and be treated as variations of the same request. Autism is genuinely heterogeneous, and that heterogeneity is what makes this category of UM uniquely hard to calibrate.

Recent estimates from the CDC’s Autism and Developmental Disabilities Monitoring Network estimated ASD prevalence among 8-year-olds at 1 in 31 — and that number continues to increase, which means case volume is increasing with it.

Evidence-based intensity benchmarks exist, but they’re not settled. The Council of Autism Service Providers (CASP) standards of care call for 30 to 40 hours per week of direct ABA intervention for young children, sustained for at least two years. Yet the research on optimal dosage, age of intervention, and concurrent service combinations has been critiqued enough that the council published a white paper in 2025 specifically to counteract studies contesting its position on intensity.

That complexity runs deeper than hours per week. ABA is commonly misperceived as one practice when it’s actually a set of different intervention practices, and the appropriate combination varies by patient. UM criteria built for more uniform conditions don’t account for that variability well. Applied without clinical context, they produce false positives (approving low-value services) and false negatives (reducing necessary treatment) in roughly equal measure.

State autism mandates create an additional layer of complexity. Mandate language often sets floors on coverage but says little about clinical standards for appropriateness review. That gap leaves medical directors to calibrate on their own.

The Overutilization Side of the Equation

Any honest conversation about autism UM must acknowledge that inappropriate approvals are also harmful. A child receiving 40 hours of ABA per week when 20 would produce equivalent outcomes is not getting better care. The excess hours carry opportunity costs for the family, and they consume resources that could reach other members waiting for services.

The spending trajectory makes this concrete. North Carolina’s Medicaid payments for ABA went from $122 million in fiscal year 2022 to a projected $639 million in fiscal year 2026 — a 423% increase in four years. That growth is driven partly by rising prevalence and expanded coverage, but it also reflects a system where intensity decisions are not always individualized.

A 2025 survey reported in Behavioral Health Business found that 80% of board-certified behavior analysts report no formal training in determining service hours, a systemic training gap in one of the most consequential clinical decisions in ABA treatment planning.

Good UM supports appropriate treatment. Sometimes that means redirecting to a less intensive level of care. And when concurrent services are authorized without coordination, they can fragment care rather than strengthen it. Health plans have a legitimate clinical role in ensuring that services are coordinated and goal aligned.

Getting the Balance Right

What balance looks like at the review level comes down to five best practices.

1. Match reviewer credentials to case complexity. ABA and broader autism cases warrant developmental and behavioral pediatric expertise, not generalist review. Specialty-matched reviewers produce more accurate determinations in both directions because they understand the clinical rationale for a given intensity level — and they can identify when that rationale is missing.

2. Require individualized clinical rationale in every review, not criteria checkboxes. The review record should document why this member, at this developmental stage, does or doesn’t require this intensity. Generic rationale fails on appeal and fails the member.

3. Update criteria to reflect current evidence. If your plan’s ABA criteria haven’t been reviewed against current literature in the past two years, they’re likely out of date. Evidence-based criteria are a prerequisite for evidence-based decisions.

4. Treat concurrent service review as a coordination question rather than a duplication question. The default lens should be how these services work together for this member — not which one to remove.

5. Track denial overturn rates by condition and reviewer type. A high overturn rate on autism-related cases at external review is a signal that the internal review process needs recalibration, not that the criteria need to be tightened further.

Better Outcomes on Both Sides

Health plans that get autism UM right don’t choose between protecting their members and managing utilization appropriately. They achieve both by investing in clinical precision at the review level. The plans that struggle are applying standardized criteria to a condition that is anything but standard.

The difference starts with the reviewer. MRIoA’s network of 700+ state-matched specialists across 150+ specialties includes developmental and behavioral pediatric expertise for every case — where the right call depends on clinical context only a matched reviewer can provide.

Schedule a clinical review consultation to discuss how your autism UM program can deliver better outcomes.

The post The Right Call on Autism: How Health Plans Can Reduce Inappropriate Denials While Ensuring Appropriate Care appeared first on MRIoA.

That distinction seems obvious. In utilization management, it’s often ignored.

Rates of anxiety, depression, and behavioral disorders among children and adolescents have reached crisis levels, driving an unparalleled demand for care. Health plans are facing pressure to build efficient, integrated care models that move cases faster and reduce administrative burden.

Behavioral health is no exception to this pressure; however, pediatric psychiatry presents a specific and underappreciated strain. Developmental context, family systems, school and social factors, and medication protocols that don’t mirror adult standards aren’t edge cases. They’re the clinical reality of nearly every case in this population. Reviewing these cases requires more than operational efficiency. It requires subspecialty depth.

For most health plans, that depth is exactly what’s missing. In utilization management, subspecialty expertise in child and adolescent psychiatry isn’t an afterthought. It’s a clinical and operational imperative.

The Exponential Demand for Child and Adolescent Psychiatric Care

The scale of the problem is no longer debatable. In 2023, roughly 1 in 5 adolescents ages 12 to 17 had a current, diagnosed mental or behavioral health condition. Between 2016 and 2023, the prevalence of diagnosed mental or behavioral health conditions among adolescents increased by 35%, with diagnosed anxiety up by 61% and depression up by 45%. These aren’t post-pandemic anomalies. They’re a structural shift in the behavioral health needs of an entire generation.

Health plans, third-party administrators, and employers need to adjust to this shift in real time.

Among adolescents with a current diagnosis who needed treatment, 61% reported difficulty accessing it in 2023, a 35% increase since 2018. When the system can’t absorb that demand in outpatient settings, cases escalate into inpatient admissions, residential placements, partial hospitalization, and intensive outpatient requests, each requiring clinical review. Every gap in the community safety net becomes a case in a utilization queue.

Here’s what makes it harder than it looks on paper: A 13-year-old presenting with acute anxiety requires a different clinical lens than an adult with the same diagnosis. It needs to account for family dynamics, school environment, trauma history, and medication considerations that aren’t identical to adult protocols. The clinical variables are different, as are the level-of-care thresholds. The stakes are even higher because the downstream effects of a wrong review for a child in formative developmental years can be consequential.

Why Pediatric Psychiatric Cases Present Unique Review Challenges

Pediatric psychiatric cases are uniquely complex. A 15-year-old presenting with severe depression may also carry a trauma history, a learning disability, and a home environment that is actively destabilizing her recovery. Comorbidity is the norm in this population, and untangling it requires a reviewer who understands how these conditions interact developmentally.

The wide spectrum of cases reflects this complexity:

• Inpatient psychiatric admissions for suicidal ideation or suicide attempts
• Residential treatment center placements for youth with chronic behavioral or trauma-related conditions
• Partial hospitalization and intensive outpatient requests following acute episodes
• Extended stays beyond initial authorization, where continued stay criteria are particularly difficult to apply in adolescents
• Concurrent medical and psychiatric admissions requiring coordination across service lines
• Medication management reviews: Prior authorization for atypical antipsychotics, stimulants, mood stabilizers, and other psychotropics in pediatric populations, where dosing, off-label use, and developmental appropriateness add complexity
• Autism spectrum disorder (ASD) and co-occurring conditions: ABA therapy authorizations, as well as reviews involving ADHD, anxiety, mood disorders, and trauma presenting alongside ASD
• Eating disorders: Anorexia, bulimia, and ARFID in adolescents often require multi-setting review across medical and psychiatric levels of care, where medical necessity criteria can be difficult to apply without subspecialty knowledge
• Substance use and dual diagnosis: Reviews involving co-occurring substance use and psychiatric conditions, where treatment setting and duration decisions are especially high-stakes
• Extended or repeated acute episodes: Cases involving frequent readmissions or chronic high utilization that require clinical pattern recognition beyond standard criteria application

Creating the Capacity for Subspecialty Review

Generalist reviewers are skilled clinicians. The problem isn’t effort — it’s fit. Reviewing child and adolescent psychiatric cases requires a clinical frame that general behavioral health training doesn’t reliably provide.

When that fit is missing, the consequences are predictable: criteria applied technically but not clinically, denials that don’t hold up under challenge, peer-to-peer conversations that go poorly, and appeals that carry real costs in administrative time, legal exposure, and regulatory risk as federal and state parity enforcement has intensified.

The obvious solution is to build this capacity internally, but today’s workforce doesn’t support it. Child and adolescent psychiatrists are among the scarcest specialists in medicine, with severe shortages across the country. For most health plans, leveraging a credentialed subspecialty review partner is a viable option to filling that gap in expertise.

What to Look for in a Behavioral Health UM Partner

Not all review organizations are equipped for this population. When evaluating a partner, four criteria matter most:

1. A credentialed panel of child and adolescent psychiatrists. Board certification in child and adolescent psychiatry is a distinct credential, earned through additional training beyond general psychiatry.
2. Familiarity with pediatric-specific criteria. InterQual, MCG, and similar tools have pediatric modules, but applying them correctly requires clinical experience with this population, not just access to the tool. Ask how reviewers are trained on pediatric criteria and how that training is maintained.
3. Subspecialty peer-to-peer capability. When decisions are challenged, peer-to-peer conversations matter. That conversation should happen between clinical equals as the standard for producing defensible outcomes and supporting the treating relationship.
4. Turnaround times that don’t sacrifice rigor. Pediatric psychiatric cases, especially those involving acute safety concerns, require both speed and clinical depth. In the hands of an experienced subspecialty reviewer, these aren’t competing priorities.

Matching Review Expertise to the Complexity of the Case

The regulatory and operational pressure on health plans to get behavioral health reviews right the first time, every time is only intensifying.

Subspecialty expertise in child and adolescent psychiatry isn’t a feature to evaluate during the next contract cycle. It’s a gap that’s costing plans right now in appeals, in peer-to-peer losses, in regulatory exposure, and in outcomes for a population that has very little margin for error.

MRIoA’s panel of board-certified child and adolescent psychiatrists brings the subspecialty depth that pediatric psychiatric UM demands with the turnaround times, peer-to-peer capability, and criteria expertise to support defensible, clinically grounded decisions at every level of care.

The post Why Subspecialty Expertise Matters in Child and Adolescent Psychiatry Utilization Management appeared first on MRIoA.

In this on-demand webinar, CredibleMind and MRIoA explore how organizations can close this gap by helping individuals:

• Recognize early signs of need
• Understand their options
• Take the right next step before issues escalate

Watch the full Behavioral Health Webinar recording for a practical framework for improving how behavioral health needs are identified, triaged, and addressed across the full continuum of care. 

The post Closing the Behavioral Health Decision Gap Webinar Recap appeared first on MRIoA.

The emerging clinical consensus positions SUD alongside conditions like diabetes, hypertension, and heart disease: a chronic illness that requires ongoing medical management, evidence-based intervention, and coordinated care across multiple specialties. For health plans and TPAs, this reframing demands a parallel evolution in how UM programs evaluate appropriate levels of care. The gap between where SUD treatment is heading and how most UM programs are currently designed represents both a clinical risk and a financial one. 

The Gap Between SUD Care Reality and UM Practice 

The American Society of Addiction Medicine (ASAM) Criteria, 4th Edition (published December 2023), organizes SUD treatment into four broad levels of care: Level 1 (Outpatient), Level 2 (Intensive Outpatient), Level 3 (Residential), and Level 4 (Medically Managed Inpatient). Within each level, decimal gradations reflect increasing clinical intensity, with the medically managed sub-levels — 2.7, 3.7, and 4 — representing the points on the continuum where active withdrawal management and biomedical monitoring are required. Yet despite this well-established framework, UM programs often default to binary thinking: inpatient withdrawal management or not, residential or outpatient. 

The data illustrates both the scale and the shifting complexity of the challenge. According to the 2024 National Survey on Drug Use and Health (NSDUH), published by SAMHSA in July 2025, an estimated 48.4 million people in the U.S. — roughly 16.8% of the population aged 12 or older — met criteria for a substance use disorder in 2024. Yet 80% of those who needed treatment did not receive it. Among those who do enter the treatment system, the stakes of appropriate level of care placement are high. This is especially true as SUD presentations grow more medically complex: polysubstance use, alcohol-related hepatic disease, opioid use disorder with cardiac and pulmonary complications, and stimulant use with psychiatric comorbidities are increasingly common clinical presentations that demand more from UM review, not less. 

Health plans and TPAs face a dual risk when UM programs are not calibrated to this complexity: 

• Overutilization: Patients placed at higher levels of care than clinical evidence supports, driving avoidable inpatient costs and occupying limited beds needed by patients who genuinely require that level of care. 

• Underutilization: Patients stepped down prematurely without clinical basis, increasing the likelihood of relapse, readmission, and higher total cost of care over time. 

The regulatory landscape reinforces the need for rigor. While all U.S. states have enacted statutes addressing mental health and SUD insurance parity, the strength and scope of these laws vary widely. State insurance commissioners are increasingly scrutinizing how health plans apply UM criteria to behavioral health relative to medical and surgical benefits, and the data in the Mental Health and SUD Insurance Parity Summary of State Laws demonstrates that most states have enacted or are actively writing legislation to strengthen parity protections. For health plans operating across multiple states, the compliance picture is not uniform, and that makes evidence-based, consistently applied clinical review all the more critical. 

 Evidence-Based Reviews Across the SUD Continuum 

Accurate SUD level-of-care determination requires more than criteria matching. Clinical nuance is high: withdrawal severity, substance type, prior treatment history, co-occurring medical and psychiatric conditions, and social determinants of health all inform appropriate level of care (LOC) in ways that algorithmic review cannot reliably capture. Physician-led review, conducted by specialists with direct clinical experience in addiction medicine, is essential. 

MRIoA’s clinical review capabilities span the full SUD continuum, ranging from Level 1 (Outpatient) through Level 4 (Medically Managed Inpatient), including the clinical intensity within those levels. Appropriate level of care placement is not a one-time determination; the ASAM framework calls for ongoing reassessment as a patient’s clinical status evolves, with the goal of stepping down to the least intensive setting that safely supports recovery. 

The integrated treatment dimension matters here as well. MRIoA’s reviewer network includes addiction psychiatrists alongside internists, hepatologists, cardiologists, and other medical specialists. As SUD presentations increasingly intersect with complex medical conditions, the ability to bring multi-specialty clinical input to a single review becomes a meaningful differentiator. The growing clinical evidence base for medication-assisted treatment (MAT) also means that pharmacy-related reviews, MAT appropriateness, and concurrent medical management are becoming standard components of UM for SUD. 

MRIoA’s Capabilities for SUD and Detox Review 

MRIoA brings specialized depth to SUD clinical review that general UM programs cannot replicate: 

• Addiction psychiatry expertise at the intersection of SUD and medical management, drawing from a panel of 40+ behavioral health specialists who bring direct clinical experience to complex, comorbid presentations. 

• Defensible, criteria-grounded determinations using ASAM, InterQual, MCG, or client-specified criteria, applied by physicians with hands-on addiction medicine experience — not algorithmic matching. 

• Same-day review capability that meets the clinical urgency inherent in detox presentations, where level-of-care decisions must be made quickly and accurately. 

• State-matched reviewer licensing across all 50 states, which is particularly important for Medicaid SUD programs operating under state-specific utilization review requirements. 

 Matching Clinical Review to the Complexity of SUD 

As SUD treatment evolves toward integrated, chronic disease management, health plans and TPAs need a clinical review partner whose expertise matches the complexity of the cases they are seeing. Getting level of care right in SUD is not primarily a cost management exercise. It is a clinical quality imperative that directly affects members’ recovery outcomes, long-term total cost of care, and compliance with evolving regulations. 

MRIoA’s detox and SUD level of care review capabilities are purpose-built for this moment, grounded in 40+ years of clinical review experience and backed by physician specialists who bring real addiction medicine expertise to every case. 

Schedule a consultation to learn how MRIoA can help your organization ensure appropriate, evidence-based care decisions for every member.  

The post Getting Level of Care Right in SUD: Clinical Review Strategies for Withdrawal Management and Level of Care Placement appeared first on MRIoA.